2021 ASTCT Virtual Fundamentals of HCT Training Course
April 24-25, 2021

Activity Overview
The Fundamentals of HCT Training Course is a 2-day conference that provides a broad overview and introduction of hematopoietic cell transplantation (HCT), also referred to as blood and marrow transplantation (BMT), as well as cellular immunotherapy (CI). Throughout the lectures, participants will be introduced to numerous aspects of the HCT-CI processes, which are designed to develop or enhance skills required in the management of patients undergoing these procedures. This course incorporates case-based learning to emphasize application of concepts taught through didactic lecture with a strong focus on the pharmacotherapeutic management.

Target Audience
The target audience for this course includes new practitioners, residents, fellows, pharmacists, nurses, and those training in this discipline.

Statement of Need:
The Fundamentals of HCT Training Course is designed to inform attendees about the latest developments in 1) treatment guidelines; 2) therapeutic regimens; 3) diseases state management; 4) supportive care therapies; 5) controversial care issues; and 6) clinical trial data.

Planning Committee, Activity Faculty, and Peer Reviewers

<table>
<thead>
<tr>
<th>Planning Committee</th>
<th>Activity Faculty</th>
<th>Peer Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Whited, PharmD, BCOP-CHAIR MD Anderson Cancer Center</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Benjamin Andrick, PharmD, BCOP Geisinger Medical Center</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Christina Bachmeier, PharmD, BCOP Moffitt Cancer Center</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Joseph Bubalo, PharmD, BCPS, BCOP Oregon Health &amp; Science University Hospital</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Ashley Teusink-Cross, PharmD, MBA, BCPS Cincinnati Children’s Hospital Medical Center</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Lauren DeRespiris, PharmD, BCOP Memorial Sloan Kettering Cancer Center</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Elizabeth DiMaggio, PharmD, BCOP Moffitt Cancer Center</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Jason Ernstberger, PharmD, BCOP UC Health</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Katie Gatwood, PharmD, BCOP Vanderbilt University</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Suzanne Carlene Gettys, PharmD, BCOP MD Anderson Cancer Center</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Arpita Gandhi, PharmD, BCOP Emory, Winship Cancer Institute</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>
Rebecca Gonzalez, PharmD, BCOP
Moffitt Cancer Center

Tatjana Grgic, PharmD, BCOP, CPP
University of North Carolina

Alison Gulbis, PharmD, BCOP
MD Anderson Cancer Center

Lauren Ice, PharmD, BCOP
Spectrum Health

Cathryn Jennisen, PharmD, BCOP
University of Minnesota

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA
Wake Forest Baptist Health

Helen Leather, BPharm
University of Florida

Susan Long, PharmD
University of Minnesota Masonic Children’s Hospital

Mariana Lucena, PharmD, BCOP
Cleveland Clinic

Zahra Mahmoudjafari, PharmD, BCOP, DPLA
University of Kansas Health System

Anthony J. Perissinotti, PharmD, BCOP
University of Michigan

Julianna Roddy, PharmD, BCOP
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Terri Lynn Shigle, PharmD, BCPS, BCOP
The University of Texas MD Anderson Cancer Center

Theresa Thakar, PharmD, BCOP
Indiana University Health

Jason Yeh, PharmD, BCOP
MD Anderson Cancer Center

Accredited Provider
This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation and Faculty</th>
<th>Learning Objectives</th>
<th>UAN</th>
<th>Hours (CEUs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00–9:15 AM</td>
<td><strong>Welcome—Opening Remarks</strong>&lt;br&gt;Dr. Laura Whited, PharmD, BCOP&lt;br&gt;University of Texas MD Anderson Cancer Center, Houston, TX</td>
<td>1. Briefly describe the history of the hematopoietic cell transplantation (HCT) field&lt;br&gt;2. Identify medical conditions in which HCT is indicated&lt;br&gt;3. Describe sources of stem cells utilized in HCT and their comparative advantages and disadvantages&lt;br&gt;4. Describe different donor types available for allogeneic HCT&lt;br&gt;5. List important resources to aid healthcare professionals caring for HCT patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:20–10:20 AM</td>
<td><strong>Introduction to Transplant</strong>&lt;br&gt;Dr. Alison Gulbis, PharmD, BCOP&lt;br&gt;University of Texas MD Anderson Cancer Center, Houston, TX</td>
<td>1. Briefly describe the history of the hematopoietic cell transplantation (HCT) field&lt;br&gt;2. Identify medical conditions in which HCT is indicated&lt;br&gt;3. Describe sources of stem cells utilized in HCT and their comparative advantages and disadvantages&lt;br&gt;4. Describe different donor types available for allogeneic HCT&lt;br&gt;5. List important resources to aid healthcare professionals caring for HCT patients</td>
<td>0391-9999-21-022-L04-P</td>
<td>1.0</td>
</tr>
<tr>
<td>10:25–11:40 AM</td>
<td><strong>Stem Cell Mobilization</strong>&lt;br&gt;Dr. Teresa Thakrar, PharmD, BCOP&lt;br&gt;Indiana University Health-Melvin and Bren Simon Cancer Center, Indianapolis, IN</td>
<td>1. Identify different stem cell sources and understand the advantages and disadvantages of using peripheral blood, bone marrow, and umbilical cord blood in HCT&lt;br&gt;2. Describe pharmacologic approaches for stem cell mobilization&lt;br&gt;3. Identify pharmacoeconomic factors to consider with stem cell mobilization&lt;br&gt;4. Summarize risk factors associated with poor stem cell mobilization and strategies for management</td>
<td>0391-9999-21-023-L04-P</td>
<td>1.25</td>
</tr>
<tr>
<td>11:40–11:50 AM</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50–12:50 PM</td>
<td><strong>Principles of Conditioning in HCT (Including Busulfan Pharmacokinetics)</strong>&lt;br&gt;Dr. Mariana Lucena, PharmD, BCOP&lt;br&gt;Cleveland Clinic, Cleveland, OH</td>
<td>1. Explain the foundation of conditioning regimens in both autologous and allogeneic hematopoietic stem cell transplantation (HCT)&lt;br&gt;2. Discuss the various therapies used in HCT conditioning regimens and doses utilized in each setting&lt;br&gt;3. Describe the different toxicity profiles of the therapies used in HCT conditioning regimens&lt;br&gt;4. Identify the key differences between reduced intensity (RIC), non-myeloablative (NMA), and myeloablative (MA) conditioning regimens</td>
<td>0391-9999-21-024-L04-P</td>
<td>1.0</td>
</tr>
<tr>
<td>12:50–1:30 PM</td>
<td><strong>Lunch</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>Learning Objectives</td>
<td>UAN</td>
<td>Hours (CEUs)</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>1:30–2:45 PM</td>
<td><strong>Immune Effector Cell Therapy Basics and Toxics</strong>&lt;br&gt;Dr. Christina Bachmeier, PharmD, BCOP&lt;br&gt;Moffitt Cancer Center, Tampa, FL</td>
<td>1. Compare and contrast the following immune effector cell (IEC) therapy products: chimeric antigen receptor cell therapy (CAR T), tumor infiltrating lymphocytes (TIL), and genetically modified T cell receptor therapy (TCR)&lt;br&gt;2. Summarize the differences between CD19 directed CAR T cell products&lt;br&gt;3. Explain the onset, symptoms, and grading of cytokine release syndrome (CRS) and CAR T cell related neurological toxicities&lt;br&gt;4. Outline the prevention and management of other adverse effects associated with CAR T cell therapy</td>
<td>0391-9999-21-025-L04-P</td>
<td>1.25</td>
</tr>
<tr>
<td>2:50PM–3:20 PM</td>
<td><strong>SOS/VOD</strong>&lt;br&gt;Dr. Katie Gatwood, PharmD, BCOP&lt;br&gt;Vanderbilt University, Nashville, TN</td>
<td>1. Describe the pathophysiology of VOD/SOS&lt;br&gt;2. Recognize the risk factors for developing VOD/SOS&lt;br&gt;3. Identify appropriate preventative strategies for VOD/SOS&lt;br&gt;4. Outline treatment options available for and outcomes managing VOD/SOS</td>
<td>0391-9999-21-026-L04-P</td>
<td>0.5</td>
</tr>
<tr>
<td>3:20–3:30 PM</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30–4:15 PM</td>
<td><strong>Post HCT Maintenance Strategies</strong>&lt;br&gt;Dr. Jason Yeh, PharmD, BCOP&lt;br&gt;University of Texas MD Anderson Cancer Center, Houston, TX</td>
<td>1. Discuss guideline recommendations and maintenance therapies utilized after autologous hematopoietic cell transplantation (aHCT) in multiple myeloma (MM), Hodgkin lymphoma (HL), and Non-Hodgkin lymphoma (NHL)&lt;br&gt;2. Explain the use of donor lymphocyte infusions (DLI) for disease management after allogeneic hematopoietic cell transplantation (alloHCT)&lt;br&gt;3. Review the evidence for the use of maintenance therapies after alloHCT in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL)</td>
<td>0391-9999-21-027-L04-P</td>
<td>0.75</td>
</tr>
</tbody>
</table>

**Program Agenda—Day 2: Sunday, April 25, 2021**

*NOTE—ALL TIMES IN CENTRAL TIME ZONE*
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker(s)</th>
<th>Learning Objectives</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:05–11:00 AM</td>
<td><strong>Fungal Infections Prophylaxis and Management</strong></td>
<td>Dr. Laura Whited, PharmD, BCOP&lt;br&gt;University of Texas MD Anderson Cancer Center, Houston, TX</td>
<td>1. Describe the epidemiology and risk factors associated with various invasive fungal infections (IFI) in the setting of hematopoietic stem cell transplant (HCT)&lt;br&gt;2. Review prophylaxis and treatment options for Candida, Aspergillus, Mucormycosis, and Pneumocystis jirovecii pneumonia (PJP)&lt;br&gt;3. Outline special considerations related to the treatment of fungal infections in HCT recipients including combination therapy, therapeutic drug monitoring, secondary prophylaxis, and dosing in obesity</td>
<td>0391-9999-21-029-L04-P 1.0</td>
</tr>
<tr>
<td>11:00–11:20 AM</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:20 AM–12:20 PM</td>
<td><strong>Acute GVHD</strong></td>
<td>Helen Leather, PharmD, BCOP&lt;br&gt;University of Florida, Gainesville, FL</td>
<td>1. Describe the pathophysiology of acute graft-versus-host-disease (aGVHD)&lt;br&gt;2. Recognize risk factors for developing aGVHD&lt;br&gt;3. Understand prophylaxis approaches available for aGVHD&lt;br&gt;4. Describe treatment options for aGVHD and steroid-refractory aGVHD</td>
<td>0391-9999-21-030-L04-P 1.0</td>
</tr>
<tr>
<td>12:20 – 12:50 PM</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:50 – 1:50 PM</td>
<td><strong>Chronic GVHD</strong></td>
<td>Dr. Rebecca Gonzalez, PharmD&lt;br&gt;Moffitt Cancer Center, Tampa, FL</td>
<td>1. Distinguish the difference between “classic” acute graft-versus-host disease (aGVHD),</td>
<td>0391-9999-21-031-L04-P 1.0</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Details</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 1:55 – 2:30 PM| **Vaccinations**                           | 1. Identify key physiologic changes and clinical considerations following hematopoietic stem cell transplant (HCT) that warrant re-vaccination of HCT recipients  
2. Outline an appropriate vaccination schedule for an HCT recipient, while taking clinical considerations into account |
|               | Dr. Zahra Mahmoudjafari, PharmD, BCOP     | Kansas University Medical Center, Kansas City, KS                                                                                 |
| 2:30 – 2:45 PM| Break                                      |                                                                                                                                        |
| 2:45 – 3:45 PM| **Special Populations in HCT Panel Discussion** | Pediatrics:  
1. Identify indications for HCT that are unique for pediatric patients  
2. Describe the impact of newborn screening on HCT in the pediatric population  
3. Identify challenges specific to pediatric dosing, pharmacokinetics, and pharmacodynamics  
Geriatrics:  
1. Describe appropriate conditioning regimens for the elderly population  
2. Recognize the differences in side effects and dosing for supportive care management for geriatric patients |
|               | Dr. Susie Long, PharmD, University of Minnesota, Minneapolis, MN  
Geriatrics: Dr. Laura Whited, PharmD, BCOP; University of Texas MD Anderson Cancer Center, Houston, TX |

**Accreditation-Pharmacists**

The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award up to 11.5 CEUs to pharmacists who complete the activity and evaluation forms. There are both knowledge-based and application-based sessions in this activity. Please see the agenda above for a listing of the ACPE Universal Activity Numbers (UANs) associated with each session.
Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the live activity. **Please submit all evaluations and credit requests no later than June 8, 2021** to ensure your credit fulfillment. CE credit cannot be awarded past 60 days from the activity date.

**METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT**

1. **Review the activity objectives and CE information**
2. **Participate in the CE activity**
3. **Complete the CE evaluation form.** This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
   - **NOTE:** There is ONE evaluation for the entire program, not one for each individual session
   - **Click here to complete the evaluation and request CE credit:**
4. **Your CE credits will be submitted electronically to the CPE Monitor.** The submission is manual, so please be advised it may take up to 2 weeks before you see your credit in your profile.
   - **If there are any questions please contact Heather Tarbox at htarbox@francefoundation.com**

**Disclosure Policy**
The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

**Activity Staff Disclosures**
The planners, reviewers, editors, staff, CME committee, and other members at The American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.

**Disclosures: Planning Committee, Activity Faculty, and Peer Reviewers**
The planners and faculty listed below report that they have no relevant financial relationships to disclose:

- Benjamin Andrick, PharmD, BCOP
- Elizabeth DiMaggio, PharmD, BCOP
- Arpita Gandhi, PharmD, BCOP
- Suzanne Carlene Gettys, PharmD, BCOP
- Rebecca Gonzalez, PharmD, BCOP
- Tatjana Grgic, PharmD, BCOP, CPP
- Lauren Ice, PharmD, BCOP
- Cathryn Jennisen, PharmD, BCOP
- LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA
- Helen Leather, BPharm
- Susan Long, PharmD
The following faculty report that they have relevant financial relationships to disclose:

- **Christina Bachmeier, PharmD, BCOP**, has conducted non-CE Consulting for Kite/GILEAD and Legend Biotech. She has also served on a non-CE speakers bureau for Novartis.
- **Joseph Bubalo, PharmD, BCPS, BCOP**, has done non-CE consulting for EUSA Pharma.
- **Jason Ernstberger, PharmD, BCOP**, has served on a non-CE speakers bureau for Seattle Genetics.
- **Katie Gatwood, PharmD, BCOP**, has served on a non-CE speakers bureau for Jazz Pharmaceuticals and has done contract research for AstraZeneca.
- **Alison Gulbis, PharmD, BCOP**, has served as an advisor to EUSA Pharma.
- **Zahra Mahmoudjafari, PharmD, BCOP, DPLA**, has conducted non-CE Consulting for Celgene, Incyte, Novartis and Omeros.
- **Ashley Teusink-Cross, PharmD, MBA, BCPS**, has served on a non-CE speakers bureau for Jazz Pharmaceuticals.
- **Anthony J. Perissinotti, PharmD, BCOP**, has done non-CE consulting for Astellas.
- **Julianna Roddy, PharmD, BCOP**, has served on a non-CE speakers bureau for Astellas and Alexion. She has served as an advisor to Novartis.

**Disclosure of Unlabeled Use**
The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational. They must also disclose limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

**Commercial Support Acknowledgment**
This activity is supported by educational grants from Incyte, Jazz, and Merck.

**Disclaimer**
The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.